Dyne Therapeutics director Brian S. Posner acquires $40,000 in common shares

Bitget2026/10/06 20:15

Dyne Therapeutics director Brian S. Posner bought 2,500 common shares at $16 per share. Directly held stake rose to 27,000 shares following the purchase. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-415584), on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Pre-orders for GTA 6 are booming and may reverse the downward trend! Citigroup raises Take-Two Interactive Software (TTWO.US) target to $270

Citigroup maintains a "Buy" rating on Take-Two Interactive Software, with a target price of $270.

智通财经•2026/11/10 06:51

Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data

FXStreet•2026/11/10 06:00

Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data

FXStreet•2026/11/10 06:00

Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks

Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.

智通财经•2026/11/10 05:57